BerGenBio (BGBIO) has announced an updated business strategy for its lead drug candidate, oral AXL inhibitor bemcentinib, which will focus on first-line (1L) non-squamous non-small cell lung cancers (NSCLCs) carrying the STK11 mutation and on hospitalised COVID-19 patients. The decision to move bemcentinib to the 1L setting could significantly broaden its target population among NSCLCs, given that c 20% of such cancers carry the STK11 mutation (~30,000 patients). Following encouraging data from ....
05 May 2022
BerGenBio - Focusing in on 1L NSCLC and COVID-19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BerGenBio - Focusing in on 1L NSCLC and COVID-19
- Published:
05 May 2022 -
Author:
Pooya Hemami -
Pages:
2
BerGenBio (BGBIO) has announced an updated business strategy for its lead drug candidate, oral AXL inhibitor bemcentinib, which will focus on first-line (1L) non-squamous non-small cell lung cancers (NSCLCs) carrying the STK11 mutation and on hospitalised COVID-19 patients. The decision to move bemcentinib to the 1L setting could significantly broaden its target population among NSCLCs, given that c 20% of such cancers carry the STK11 mutation (~30,000 patients). Following encouraging data from ....